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Abstract: Selectins mediate tethering and rolling of leukocytes to the vascular endothelium,
the first adhesive step in the recruitment of immune cells to inflamed tissues. Thus, selectins
play a key role in the pathogenesis of common inflammatory skin disorders such as atopic
dermatitis or psoriasis. As a consequence of their key functions, selectins have received much
attention as potential target structures for new therapies. Indeed, a number of agents including
small-molecule as well as peptide compounds interfering with selectin functions have been
developed to treat inflammatory disorders. However, many of the selectin-directed compounds
have not held up to the high expectations, in some cases due to overlapping and mutually
compensating functions of selectins or suboptimal pharmacokinetic properties of the
compounds, while other agents appear to be more promising candidates and have already
entered clinical trials. Selectively targeting the functions of one or several selectins involved
in the cascade of leukocyte recruitment promises exciting new therapeutic options, but, at the
same time, bears considerable imponderables, which will be discussed in this review article.
Keywords: lymphocyte recruitment, adhesion molecules, chemokines, inflammation, target
molecules, selectins
Introduction
Recruitment of lymphocytes in a tissue-specific fashion is, on the one hand, a
requirement for immune surveillance and defense against pathogens and tumors,
but, on the other hand, plays a key role in the pathogenesis of inflammatory diseases,
such as psoriasis, eczematous disorders, drug-induced eruptions, or lichen planus of
the skin (Groves and Kupper 1996; Robert and Kupper 1999). Consequently, insight
into mechanisms of leukocyte recruitment to the skin is essential not only for our
understanding of the pathophysiology of inflammatory skin disorders, but also for
the development of novel and selective therapies to treat such diseases, which heavily
impact quality of life as well as the economic burden of healthcare systems worldwide.
Given that the first steps of tissue-selective trafficking of leukocytes are mediated
primarily by selectins, these molecules are being explored as promising therapeutic
target structures.
Tethering and rolling of leukocytes: the selectin-
mediated first contact to the vessel wall
The first steps of leukocyte localization to all tissues include tethering and rolling
along the vessel wall (Figure 1) – rather loose and transient adhesive interactions
that are essential for the subsequent firm adhesion, activation, and transmigration
(von Andrian and Mackay 2000). Members of the selectin family of adhesion
molecules are the primary mediators of these initial contacts (Groves et al 1991;
Shimizu et al 1991; von Andrian et al 1991; Smith et al 1993; Springer 1994; Butcher
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and Picker 1996). Selectins are single-chain transmembrane
adhesion molecules, which have been named for their lectin-
like domain that attaches to carbohydrate ligands presented
on glycoprotein scaffolds (Varki 1994; Feizi 2001; Ley
2001). Three selectins have been described: E- and P-selectin
are expressed by endothelial cells, and L-selectin is
expressed by leukocytes. E-selectin (CD62E) is primarily
regulated on the transcriptional level and is strongly induced
upon activation of endothelial cells by proinflammatory
stimuli (Cotran and Gimbrone 1986; Bevilacqua and
Stengelin 1989). In contrast, P-selectin (CD62P) is rapidly
mobilized to the cell surface from its storage vesicles, the
cytoplasmic Weibel-Pallade bodies, upon activation of
endothelial cells (Bonfanti and Furie 1989; McEver and
Beckstead 1989). In addition, there is some transcriptional
regulation of P-selectin (Ulbrich et al 2003). The pivotal
role of P- and E-selectin for lymphocyte rolling has been
demonstrated in a large variety of experimental approaches
interfering with adhesive interactions of selectins and their
carbohydrate ligands (Carlos and Harlan 1994; Todderud
et al 1997). Of note, several studies have demonstrated
considerably overlapping and mutually compensating
functions of the selectin family members, a finding that
raises important consequences and constraints for the
rational design of selectin-blocking drugs (Labow et al 1994;
Jung and Ley 1999; Weninger et al 2000; Collins et al 2001).
Consistent with these studies, a function-blocking antibody
specifically directed against E-selectin did not significantly
alleviate psoriasis, one of the most common chronic
inflammatory skin disorders, in a clinical trial (Bhushan et
al 2002). Likewise, specifically blocking L-selectin in a
recent controlled clinical trial has failed to improve psoriatic
lesions (Hardtke et al 2005). These observations in clinical
settings have strongly supported and complemented the
results from experimental studies showing that some
selectin-mediated functions may be redundant and that
interfering with a single selectin alone is not sufficient to
interrupt the inflammatory chains in some inflammatory
diseases. This notion is further corroborated by several
small-molecule compounds that interfere with the functions
Figure 1 Molecular interactions involved in lymphocyte extravasation in the skin (modified from von Andrian and Mackay 2000; Schön et al 2003). The upper part of
the figure depicts key steps of interactions with the endothelial lining resulting in extravasation of lymphocytes. The bottom part shows selected adhesion molecules
which mediate these events.
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of more than one selectin. The list of such compounds
includes efomycine M, a non-carbohydrate macrolide
inhibitor of both E- and P-selectin functions. Blocking both
E- and P-selectin by efomycine M significantly diminished
rolling of leukocytes on cutaneous microvessels and
markedly alleviated chronic inflammatory skin conditions
in a T cell-mediated murine model of psoriasis as well as in
human psoriatic skin transplanted onto scid/scid mice
(Schön et al 2002). Another promising example exhibiting
broader activity against all three known selectins is
bimosiamose, a compound that appeared to be efficacious
in early clinical trials (Aydt and Wolff 2002–2003; Hicks et
al 2005). Likewise, broader clinical efficacy may be expected
from some other recently described compounds interfering
with the functions of more than one selectin (Boehncke and
Schön 2003; Ulbrich et al 2003).
The lymphocyte-expressed L-selectin (CD62L) binds to
endothelial cell selectin ligands (Figure 1). Although some
of its ligands, such as PNAd (Peripheral Node Addressin),
may be induced in chronic inflammatory skin disorders, the
contribution of L-selectin to cutaneous recruitment of
lymphocytes appears to be limited due to its preferential
expression by naive and a subpopulation of memory T cells
rather than activated T cells. Thus, it has been proposed
that L-selectin/PNAd interactions may be more important
for extravasation of naive T cells in lymph nodes (von
Andrian and Mempel 2003; Ley and Kansas 2004), a
prerequisite for the priming of naive T lymphocytes. The
topographic distribution of L-selectin at the tips of microvilli
of rolling lymphocytes is thought to be important for easy
contact formation with endothelial ligands (Fors et al 2001).
Following ligand binding, L-selectin is shed from the cell
surface at the trailing edge of rolling lymphocytes. The
shedding of L-selectin is a proteolytic process mediated by
metalloproteases (Condon et al 2001; Zhao et al 2001). It is
thought that shedding is required for proper lymphocyte
rolling (Hafezi-Moghadam and Ley 1999), since inhibition
of L-selectin shedding resulted in increased LFA-1/ICAM-
1-mediated firm adhesion and, consecutively, transmigration
of lymphocytes (Hafezi-Moghadam et al 2001), supporting
the hypothesis of a regulatory function of the shedding
process.
In addition to the expression of L-selectin, lymphocytes
express transmembrane glycoproteins bearing Sialyl-Lewis
X
(sLe
X) moieties, that function as E- and P-selectin ligands
(Varki 1994). Among these ligands, the sLeX-bearing CLA
(cutaneous lymphocyte-associated antigen), a specially
glycosylated form of PSGL-1 (P-selectin glycoprotein
ligand-1, CD162) (Fuhlbrigge et al 1997), is preferentially
expressed by lymphocytes localizing to the skin.
Accumulating experimental evidence has been published
demonstrating that CLA is indeed functionally involved in
tissue-specific recruitment to this organ (Picker et al 1990,
1991). Topographic specialization of microvascular
endothelial cells within the skin is suggested by the
observation that CLA-bearing T lymphocytes appear to
extravasate preferentially through the endothelium of the
superficial dermal plexus (Kunstfeld et al 1997), a cutaneous
compartment potentially accessible for topically applied
selectin inhibitors.
Selectin-mediated rolling of lymphocytes is com-
plemented by VLA-4 (very late-activation antigen-4,
CD49d/CD29), a heterodimeric adhesion receptor of the
integrin family that binds to VCAM-1 (vascular cell
adhesion molecule-1) and MAdCAM-1 (mucosal addressin
cell adhesion molecule-1), two members of the
immunoglobulin (Ig) superfamily of adhesion molecules
(Figure 1). It has been reported that VLA-4 also mediates
rolling of leukocyte subsets under certain conditions (Berlin
et al 1995; Reinhardt et al 1997; Singbartl et al 2001). It is
thought that its involvement in lymphocyte rolling is due,
at least in part, to the topographic presentation of VLA-4
on microvilli of rolling cells, similar to the decoration of L-
selectin, thus enabling easy contact formation with
endothelial cell-expressed counter-receptors (Berlin et al
1995). The ligand binding affinity of VLA-4 can be rapidly
up-regulated via the p56
lck Src kinase signaling pathway
following T lymphocyte stimulation (Feigelson et al 2001).
This rapid change in integrin activity is thought to be crucial
for the transition from rolling to firm adhesion of
lymphocytes. While some aspects of the interplay of
VLA-4- and selectin-mediated adhesive interactions
involved in lymphocyte rolling still remain to be unraveled,
it appears that there is some redundancy in their functions.
In cutaneous inflammation in rats, all three receptors,
E-selectin, P-selectin, and VLA-4, are apparently required
for rolling of memory T lymphocytes (Issekutz AC and
Issekutz TB 2002). It is possible that tissue-specific (micro)-
environmental factors regulate their relative contributions
to lymphocyte recruitment. In addition to VLA-4, the
integrin LFA-1 has been reported to mediate neutrophil
rolling under certain conditions (Henderson et al 2001), and
both VLA-4 and LFA-1 can mediate selectin-independent
recruitment of neutrophils and monocytes to sites of chronic
inflammation (Birner et al 2000). Fractalkine may be another
player contributing to endothelial capture and firm adhesionTherapeutics and Clinical Risk Management 2005:1(3) 204
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of leukocytes without an involvement of selectins (Fong et
al 1998; Haskell et al 2000).
Finally, in addition to rolling of lymphocytes through
direct contact to the endothelial lining, recent research has
highlighted the importance of platelets for rolling under
certain conditions (Klinger and Jelkmann 2002; Liu and
Kubes 2003). While P-selectin has been implicated in
adhesive interactions of platelets and leukocytes, the exact
contribution of this process to cutaneous inflammation has
not been completely defined yet (Geng et al 2004; Ludwig
et al 2004).
Selectins as molecular targets for
antiinflammatory therapies
Given that selectins mediate the critical first step in the
cascade of leukocyte recruitment during inflammatory
responses, it is not surprising that these molecules have
received much attention as potential target structures for
selective and specific therapies. Indeed, few areas in
biomedical and pharmaceutical research reflect the
excitement and enthusiasm, but also a number of drawbacks
and disappointments associated with new developments as
vividly as selectin-directed antiinflammatory strategies
targeting lymphocyte extravasation. Indeed, as they appear
to meet the “desire” for a mechanistic basis of diseases and,
consecutively, rational therapeutic strategies, selectins are
appealing target structures (Boehncke and Schön 2003;
Schön et al 2003). This is reflected by a variety of selectin-
directed agents including small-molecule compounds,
carbohydrate mimetics, and antibodies generated by several
companies to treat inflammatory disorders (synopsis shown
in Table 1). However, a closer look at the complex and
intertwined molecular crosstalk underlying lymphocyte
recruitment may dampen some illusions or dishearten
overenthusiastic approaches. In addition, recruitment to
inflamed tissues may be tightly connected with other cellular
functions of immunocytes such as chemokine receptor-
mediated activation that follows selectin-mediated adhesion.
As a consequence, inflammatory diseases encountered by
clinicians are rarely predictable from single molecular
pathways, and the design or selection of compounds
targeting specific molecules involved in the inflammatory
cascade is often difficult and may face considerable
imminent problems (Kaila and Thomas 2002). This is
reflected by the fact that some of the programs searching
for inhibitors of the selectin family have been stopped for
the indication of inflammatory disorders (Table 1), a notion
that may reflect inherent difficulties in targeting this very
initial step of leukocyte recruitment.
Overall, there are several challenges that may make
approaches to target molecules involved in leukocyte
recruitment very complex and unpredictable, and this is
mirrored by the fact that some of the previous approaches
were not satisfying in preclinical or clinical trials. This
includes trials using the sialyl Lewis
X-mimetic Cylexin (Kerr
et al 2000), an anti E-selectin-directed monoclonal antibody
(Bhushan et al 2002), or a L-selectin-directed antibody
(Hardtke et al 2005). Several reasons, which are not mutually
exclusive, can be delineated:
1. Specificity for only one selectin or a suboptimal
combination of selectin specificities;
2. Low IC50 values;
Table 1 Selectin-directed compounds developed for the treatment of inflammatory disorders
Target Compound Company Status Reference
Selectins CY-1503 Cytel Corp Preclinical Kerr et al 2000
Selectins BMS-190394 BMS Preclinical Birnbaum et al 1997 
Selectins Aventis Preclinical Marinier et al 2001
Selectins OC-229648 Ontogen Kanebo Preclinical
Selectins efomycine M none Preclinical Schön et al 2002
E-selectin ESA-2 Novartis Preclinical Thomson et al 1993; Bantely and Ernst 2001; Hafezi-Moghadam et al
2001; Biedermann et al 2002
Selectins OJ- R9188 Nippon Organon  Preclinical Ikegami-Kuzuhara et al 2001
Selectins TBC-1269 Texas Biotechnology Phase I/II Abraham et al 1999;  Anaya-Prado et al 2002
Revotar
E- and P-selectin PS3 None Preclinical Yvin et al 2002
E- and P-selectin EP-5C7 Protein Design Labs Phase I Berg et al 1995;  Alon et al 1998 
E- and L-selectin EL-246 LygoCyte Preclinical Carraway et al 1998
E-selectin CDP-850 Celltech Phase II Bhushan et al 2002
P-selectin rhPSGL-1 Ig Genetics Institute  Phase II Khor et al 2000
L-selectin LD201t1 WyethNeXStar Preclinical Hicke et al 1996Therapeutics and Clinical Risk Management 2005:1(3) 205
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3. Short half-lives or other unfavorable pharmacokinetic
properties; or
4. Lability of selectin–selectin ligand interaction, which is
essential for short-lived lymphocyte–endothelial
interactions.
So, what are the challenges that we are facing? Perhaps the
most important reason for the limited predictability of
antiinflammatory approaches through targeting selectins is
functional redundancy; ie, as outlined above, selectins may
have considerable functional overlaps. In particular, this is
true for endothelial E- and P-selectin (Labow et al 1994;
Jung and Ley 1999; Collins et al 2001), allowing them to
compensate for each other in case of loss of function of one
of the players. While prominent examples have been
reported in the selectin field (Labow et al 1994; Jung and
Ley 1999; Collins et al 2001), this problem is by no means
unique to this family, since similar (maybe even more
pronounced) redundancy problems are faced when targeting
the chemokine/chemokine receptor system (Zlotnik and
Yoshie 2000; Onuffer and Horuk 2002).
It was long believed that CLA expressed by skin-homing
T cells is mainly an E-selectin ligand (Berg et al 1991;
Rossiter et al 1994). However, the carbohydrate moieties
mediating tethering and rolling of lymphocytes along the
endothelial lining also bind to P- and L-selectin (Labow et
al 1994; Jung and Ley 1999; Collins et al 2001). Activated
endothelial cells in inflamed tissues may express PNAd, a
ligand for lymphocyte-expressed L-selectin, although
L-selectin itself is not expressed by endothelial cells. This
mechanism may compensate for lymphocyte rolling when
E- and P-selectin are selectively blocked, eg, by small-
molecule- or antibody-based therapeutics (Alon and
Feigelson 2002; Dwir et al 2002). In addition, T cells may
roll along the vessel wall through cluster formation with
activated platelets (Diacovo et al 1996, 1998; Ludwig et al
2004), and even in the complete absence of selectins and
their ligands, rolling of some lymphocytes may occur
through interactions of endothelial VCAM-1 with the
lymphocyte-expressed VLA-4 integrin (Jung and Ley 1999).
Similar problems may be encountered when glycosylation
of selectin ligands is targeted, eg, by proteasome inhibitors
(Zollner et al 2002). Rational drug design of compounds
modeled after functionally relevant groups, or high-
throughput screenings assessing the functions of single
molecules as readout parameters might, therefore, confront
the aforesaid problems.
Recent examples of approaches that may have been too
specific (thus neglecting functional redundancy) include the
failure of antibodies directed specifically against E-selectin
or L-selectin to alleviate psoriasis in controlled clinical trials
(Bhushan et al 2002; Hardtke et al 2005), or the limited
clinical response to recombinant human (rh) PSGL-1 Ig
(Khor et al 2000). In that respect, concepts interfering with
a group of molecules with overlapping functions involved
in a given step of lymphocyte extravasation may bear some
advantages, such as efomycine M or the TBC-1269
compound (bimosiamose) blocking several selectins
(Abraham et al 1999; Schön et al 2002). However, the
success of such broader strategies is not guaranteed, as
exemplified by the insufficient response to the pan-selectin
inhibitor OJ-R9188 (Ikegami-Kuzuhara et al 2001).
Another group of potential problems relates to
unexpected effects; ie, targeting of certain molecules may
result in unexpected or even paradoxical outcomes. As a
possible example, a regulatory effect of chemokines on
lymphocyte rolling has recently been identified, inasmuch
as chemokines may exert (paradoxical) antiadhesive effects
through G-protein-independent destabilization of L-selectin
(Grabovsky et al 2002).
An alternative or additional approach to target leukocyte
rolling along the skin microvasculature through modulation
of selectin functions is interference with fucosyltransferase-
(FucT)-VII and -IV, key enzymes in the generation of
selectin-ligand carbohydrate moieties. The rationale behind
this approach comes from the observation that selectin ligand
activity is absent or reduced dramatically in FucT-VII single
or FucT-IV and -VII double knockout mice. Cutaneous
inflammatory responses are markedly reduced in several
models of inflammatory diseases using animals deficient
for one or both enzymes (Maly et al 1996; Weninger et al
2000; Homeister et al 2001; Asadullah et al 2002). The
relevance of this impaired function in human patients is
highlighted by leukocyte adhesion deficiency II (LAD II),
a rare congenital immune defect (Gu et al 2004). One
potential approach to interfere with expression of FucT-VII
is inhibiting its transcription using NF-κB inhibitors such
as the proteasome inhibitor PS-519 or antioxidants such as
N-acetyl cysteine (Zollner et al 2002). However, given that
interfering with the pleiotropic effects of NF-κB may have
many other effects on the immune system and other cells,
the low specificity of this approach is a potential
disadvantage. Another strategy might encompass the
inhibition of FucT activity by small-molecule compounds.
As posttranslational glycosylation of proteins by FucTs
occurs in the Golgi apparatus, it might, however, be
challenging to identify small molecules penetrating both theTherapeutics and Clinical Risk Management 2005:1(3) 206
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cell membrane and the Golgi membrane. At least two
different companies (GlaxoSmithKline, Kyowa Hakko
Kogyo) have reported recombinant expression of FucT-VII
protein (Shinkai et al 1997; Smithers et al 1997), suggesting
that this latter approach has been pursued. In addition,
panosialins A and B have been isolated as inhibitors of FucT-
VII from the culture broth of Streptomyces sp., which inhibit
FucT-VII activity and cell binding to immobilized selectin
ligands in vitro (Shinoda et al 1998).
Overall, it is generally not easy to predict the clinical
feasibility and efficacy of selectively targeting selectin
functions in the treatment of inflammatory disorders. It
appears that at least two levels of complex interactions
influence the success of therapeutic strategies aimed at
lymphocyte extravasation; ie, distinct players mediating
consecutive pathogenic steps (“vertical”, eg, chemokine
receptor activation followed by integrin-mediated firm
arrest), as well as synchronous action of several molecules
mediating a given event (“horizontal”, eg, selectins and
chemokine receptors simultaneously involved in lymphocyte
rolling).
Acknowledgments
This work was supported by a Rudolf Virchow Award from
the Deutsche Forschungsgemeinschaft to MPS.
References
Abraham WM, Ahmed A, Sabater JR, et al. 1999. Selectin blockade
prevents antigen-induced late bronchial responses and airway
hyperresponsiveness in allergic sheep. Am J Respir Crit Care Med,
159:1205–14.
Alon R, Chen S, Fuhlbrigge R, et al. 1998. The kinetics and shear threshold
of transient and rolling interactions of L-selectin with its ligand on
leukocytes. Proc Natl Acad Sci U S A, 95:11631–6.
Alon R, Feigelson S. 2002. From rolling to arrest on blood vessels:
leukocyte tap dancing on endothelial integrin ligands and chemokines
at sub-second contacts. Semin Immunol, 14:93–104.
Anaya-Prado R, Ramos-Kelly JR, Toledo-Pereyra LH, et al. 2002. Multiple
selectin blockade with a small-molecule selectin inhibitor does not
affect survival after a second inflammatory challenge with nonlethal
LPS. J Invest Surg, 15:171–80.
Asadullah K, Lowe JB, Schottelius A. 2002. Differential influences on
skin inflammation models in mice deficient of alpha(1,3)fuco-
syltransferase VII. Arch Dermatol Res, 294:43.
Aydt E, Wolff G. 2002–2003. Development of synthetic pan-selectin
antagonists: a new treatment strategy for chronic inflammation in
asthma. Pathobiology, 70:297–301.
Bantely R, Ernst B. 2001. Synthesis of Sialyl Lewis X mimetics.
Modifications of the 6-position of galactose. Bioorg Med Chem Lett,
11:459–62.
Berg EL, Fromm C, Melrose J, et al. 1995. Antibodies cross-reactive with
E- and P-selectin block both E- and P-selectin functions. Blood, 85:
31–7.
Berg EL, Yoshino T, Rott LS, et al. 1991. The cutaneous lymphocyte antigen
is a skin lymphocyte homing receptor for the vascular lectin endothelial
cell-leukocyte adhesion molecule-1. J Exp Med, 174:1461–6.
Berlin C, Bargatze RF, Campbell JJ, et al. 1995. Alpha 4 integrins mediate
lymphocyte attachment and rolling under physiologic flow. Cell,
80:413–22.
Bevilacqua MP, Stengelin S. 1989. Endothelial leukocyte adhesion
molecule-1: an inducible receptor for neutrophils related to
complement regulatory proteins and lectins. Science, 243:1160–3.
Bhushan M, Bleiker TO, Ballsdon AE, et al. 2002. Anti-E-selectin is
ineffective in the treatment of psoriasis: a randomized trial. Br J
Dermatol, 146:824–31.
Biedermann T, Schwärzler C, Lametschwandtner G, et al. 2002. Targeting
CLA/E-selectin interactions prevents CCR4-mediated recruitment of
human Th2 memory cells to human skin in vivo. Eur J Immunol,
32:3171–80.
Birnbaum Y, Patterson M, Kloner RA. 1997. The effect of CY-1503, a
sialyl LewisX analog blocker of the selectin adhesion molecules, on
infarct size and “no reflow” in the rabbit model of acute infarction/
reperfusion. J Mol Cell Cardiol, 29:2013–25.
Birner U, Issekutz TB, Walter U, et al. 2000. The role of alpha(4) and
LFA-1 integrins in selectin-independent monocyte and neutrophil
migration to joints of rats with adjuvant arthritis. Int Immunol, 12:
141–50.
Boehncke WH, Schön MP. 2003. Interfering with leukocyte rolling – a
promising therapeutic approach in inflammatory skin disorders? Trends
Pharmacol Sci, 24:49–52.
Bonfanti R, Furie BC. 1989. PADGEM (GMP140) is a component of
Waibel-Palade bodies of human endothelial cells. Blood, 73:
1109–12.
Butcher EC, Picker LJ. 1996. Lymphocyte homing and homeostasis.
Science, 272:60–6.
Carlos TM, Harlan JM. 1994. Leukocyte-endothelial adhesion molecules.
Blood, 84:2068–101.
Carraway MS, Welty-Wolf KE, Kantrow SP, et al. 1998. Antibody to E-
and L-selectin does not prevent lung injury or mortality in septic
baboons. Am J Respir Crit Care Med, 157:938–49.
Collins RG, Jung U, Ramirez M, et al. 2001. Dermal and pulmonary
inflammatory disease in E-selectin and P-selectin double-null mice is
reduced in triple-selectin-null mice. Blood, 98:727–35.
Condon TP, Flournoy S, Sawyer GJ, et al. 2001. ADAM17 but not ADAM10
mediates tumor necrosis factor-alpha and L-selectin shedding from
leukocyte membranes. Antisense Nucleic Acid Drug Dev, 11:107–16.
Cotran RS, Gimbrone MAJ. 1986. Induction and detection of a human
endothelial activation antigen in vivo. J Exp Med, 164:661–6.
Diacovo TG, Catalina MD, Siegelman MH, et al. 1998. Circulating
activated platelets reconstitute lymphocyte homing and immunity in
L-selectin-deficient mice. J Exp Med, 187:197–204.
Diacovo TG, Puri KD, Warnock RA, et al. 1996. Platelet-mediated
lymphocyte delivery to high endothelial venules. Science, 273:
252–5.
Dwir O, Steeber DA, Schwarz US, et al. 2002. L-selectin dimerization
enhances tether formation to properly spaced ligand. J Biol Chem,
277:21130–9.
Feigelson SW, Grabovsky V, Winter E, et al. 2001. The Src kinase p56(lck)
up-regulates VLA-4 integrin affinity. Implications for rapid
spontaneous and chemokine-triggered T cell adhesion to VCAM-1
and fibronectin. J Biol Chem, 276:13891–901.
Feizi T. 2001. Carbohydrate ligands for the leukocyte-endothelium adhesion
molecules, selectins. Results Probl Cell Differ, 33:201–23.
Fong AM, Robinson LA, Steeber DA, et al. 1998. Fractalkine and CX3CR1
mediate a novel mechanism of leukocyte capture, firm adhesion, and
activation under physiologic flow. J Exp Med, 188:1413–19.
Fors BP, Goodarzi K, von Andrian UH. 2001. L-selectin shedding is
independent of its subsurface structures and topographic distribution.
J Immunol, 167:3642–51.Therapeutics and Clinical Risk Management 2005:1(3) 207
Selectin inhibitors in skin disease
Fuhlbrigge RC, Kieffer JD, Armerding D, et al. 1997. Cutaneous
lymphocyte antigen is a specialized form of PSGL-1 expressed on
skin-homing T cells. Nature, 389:978–81.
Geng JG, Chen M, Chou KC. 2004. P-selectin cell adhesion molecule in
inflammation, thrombosis, cancer growth and metastasis. Curr Med
Chem, 11:2153–60.
Grabovsky V, Dwir O, Alon R. 2002. Endothelial chemokines destabilize
L-selectin-mediated lymphocyte rolling without inducing selectin
shedding. J Biol Chem, 277:20640–50.
Groves RW, Allen MH, Barker JN, et al. 1991. Endothelial leukocyte
adhesion molecule-1 (ELAM-1) expression in cutaneous
inflammation. Br J Dermatol, 124:117–23.
Groves RW, Kupper TS. 1996. Leukocyte recruitment in cutaneous
inflammation. In Peltz G (ed). Leukocyte recruitment in inflammatory
disease. New York: Springer. p 71–84.
Gu YC, Bauer TR, Ackermann MR, et al. 2004. The genetic immuno-
deficiency disease, leukocyte adhesion deficiency, in humans, dogs,
cattle, and mice. Comp Med, 54:363–72.
Hafezi-Moghadam A, Ley K. 1999. Relevance of L-selectin shedding for
leukocyte rolling in vivo. J Exp Med, 189:939–48.
Hafezi-Moghadam A, Thomas KL, Prorock AJ, et al. 2001. L-selectin
shedding regulates leukocyte recruitment. J Exp Med, 193:863–72.
Hardtke M, Friedrich M, Philipp S, et al. 2005. Anti-L-selectin therapy is
not effective in psoriasis: a randomized trial [abstract]. Arch Dermatol
Res, 296:427.
Haskell CA, Cleary MD, Charo IF. 2000. Unique role of the chemokine
domain of fractalkine in cell capture. Kinetics of receptor dissociation
correlate with cell adhesion. J Biol Chem, 275:34183–9.
Henderson RB, Lim LH, Tessier PA, et al. 2001. The use of lymphocyte
function-associated antigen (LFA)-1-deficient mice to determine the
role of LFA-1, Mac-1, and alpha4 integrin in the inflammatory response
of neutrophils. J Exp Med, 194:219–26.
Hicke BJ, Watson SR, Koenig A, et al. 1996. DNA aptamers block L-
selectin function in vivo. Inhibition of human lymphocyte trafficking
in SCID mice. J Clin Invest, 98:2688–92.
Hicks AE, Abbitt KB, Dodd P, et al. 2005. The anti-inflammatory effects
of a selectin ligand mimetic, TBC-1269, are not a result of competitive
inhibition of leukocyte rolling in vivo. J Leukoc Biol, 77:59–66.
Homeister JW, Thall AD, Petryniak B, et al. 2001. The alpha(1,3)fucosyl-
transferases FucTIV and Fuc-TVII exert collaborative control over
selectin-dependent leukocyte recruitment and lymphocyte homing.
Immunity, 15:115–26.
Ikegami-Kuzuhara A, Yoshinaka T, Ohmoto H, et al. 2001. Therapeutic
potential of a novel synthetic selectin blocker, OJ-R9188, in allergic
dermatitis. Br J Pharmacol, 134:1498–504.
Issekutz AC, Issekutz TB. 2002. The role of E-selectin, P-selectin, and
very late activation antigen-4 in T lymphocyte migration to dermal
inflammation. J Immunol, 168:1934–9.
Jung U, Ley K. 1999. Mice lacking two or all three selectins demonstrate
overlapping and distinct functions for each selectin. J Immunol,
162:6755–62.
Kaila N, Thomas BE. 2002. Design and synthesis of sialyl LewisX mimics
as E- and P-selectin inhibitors. Med Res Rev, 22:566–601.
Kerr KM, Auger WR, Marsh JJ, et al. 2000. The use of cylexin (CY-1503)
in prevention of reperfusion lung injury in patients undergoing
pulmonary thromboendarterectomy. Am J Respir Crit Care Med,
162:14–20.
Khor SP, McCarthy K, DuPont M, et al. 2000. Pharmacokinetics,
pharmacodynamics, allometry, and dose selection of rPSGL-Ig for
phase I trial. J Pharmacol Exp Ther, 293:618–24.
Klinger MH, Jelkmann W. 2002. Role of blood platelets in infection and
inflammation. J Interferon Cytokine Res, 22:913–22.
Kunstfeld R, Lechleitner S, Groger M, et al. 1997. HECA-452+ T cells
migrate through superficial vascular plexus but not through deep
vascular plexus endothelium. J Invest Dermatol, 108:343–8.
Labow MA, Norton CR, Rumberger JM, et al. 1994. Characterization of
E-selectin-deficient mice: demonstration of overlapping function of
the endothelial selectins. Immunity, 1:709–20.
Ley K. 2001. Functions of selectins. Results Probl Cell Differ, 33:
177–200.
Ley K, Kansas GS. 2004. Selectins in T-cell recruitment to non-lymphoid
tissues and sites of inflammation. Nat Rev Immunol, 4:325–36.
Liu L, Kubes P. 2003. Molecular mechanisms of leukocyte recruitment:
organ-specific mechanisms of action. Thromb Haemost, 89:213–20.
Ludwig RJ, Schultz JE, Boehncke WH, et al. 2004. Activated, not resting,
platelets increase leukocyte rolling in murine skin utilizing a distinct
set of adhesion molecules. J Invest Dermatol, 122:830–6.
Maly P, Thall A, Petryniak B, et al. 1996. The alpha(1,3)fucosyltransferase
Fuc-TVII controls leukocyte trafficking through an essential role in
L-, E-, and P-selectin biosynthesis. Cell, 86:643–53.
Marinier A, Martel A, Bachand C, et al. 2001. Novel mimics of sialyl
Lewis X; design, synthesis and biological activity in a series of 2- and
3-malonate substituted galactoconjugates. Bioorg Med Chem, 9:
1395–427.
McEver RP, Beckstead JH. 1989. GMP-140, a platelet alpha granule
membrane protein, is also synthesized by vascular endothelial cells
and is localized in Waibel-Palade bodies. J Clin Invest, 84:92–9.
Onuffer JJ, Horuk R. 2002. Chemokines, chemokine receptors and small-
molecule antagonists: recent developments. Trends Pharmacol Sci,
23:459–67.
Picker LJ, Kishimoto TK, Smith CW, et al. 1991. ELAM-1 is an adhesion
molecule for skin-homing T-cells. Nature, 349:796–9.
Picker LJ, Michie SA, Rott LS, et al. 1990. A unique phenotype of skin-
associated lymphocytes in humans. Preferential expression of the
HECA-425 epitope by benign and malignant T cells at cutaneous sites.
Am J Pathol, 136:1053–68.
Reinhardt PH, Elliott JF, Kubes P. 1997. Neutrophils can adhere via
alpha4beta1-integrin under flow conditions. Blood, 89:3837–46.
Robert C, Kupper TS. 1999. Inflammatory skin diseases, T cells, and
immune surveillance. N Engl J Med, 341:1817–28.
Rossiter H, van Reijsen F, Mudde GC, et al. 1994. Skin disease-related T
cells bind to endothelial selectins: expression of cutaneous lymphocyte
antigen (CLA) predicts E-selectin but not P-selectin binding. Eur J
Immunol, 24:205–10.
Schön MP, Krahn T, Schön M, et al. 2002. Efomycine M, a new specific
inhibitor of selectin, impairs leukocyte adhesion and alleviates
cutaneous inflammation. Nat Med, 8:366–72.
Schön MP, Zollner TM, Boehncke WH. 2003. The molecular basis of
lymphocyte recruitment to the skin: clues for pathogenesis and
selective therapies of inflammatory disorders. J Invest Dermatol,
121:951–62.
Shimizu Y, Newman W, Gopal TV, et al. 1991. Four molecular pathways
of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and
ELAM-1 and changes in pathway hierarchy under different activation
conditions. J Cell Biol, 113:1203–12.
Shinkai A, Shinoda K, Sasaki K, et al. 1997. High-level expression and
purification of a recombinant human alpha(1,3)fucosyltransferase in
baculovirus-infected insect cells. Prot Exp Purif, 10:379–85.
Shinoda K, Shitara K, Yoshihara Y, et al. 1998. Panosialins, inhibitors of
an alpha 1,3 fucosyltransferase Fuc-VII, suppress the expression of
selectin ligands on U937 cells. Glycoconj J, 15:1079–83.
Singbartl K, Thatte J, Smith ML, et al. 2001. A CD2-green fluorescence
protein-transgenic mouse reveals very late antigen-4-dependent CD8+
lymphocyte rolling in inflamed venules. J Immunol, 166:7520–6.
Smith CH, Barker JN, Morris RW, et al. 1993. Neuropeptides induce rapid
expression of endothelial cell adhesion molecules and elicit
granulocytic infiltration in human skin. J Immunol, 151:3274–82.
Smithers N, Kelly VA, Witham SJ, et al. 1997. Expression of a secreted
form of human alpha(1,3)fucosyltransferase VII from insect cells.
Biochem Soc Trans, 25:426.Therapeutics and Clinical Risk Management 2005:1(3) 208
Schön
Springer TA. 1994. Traffic signals for lymphocyte recirculation and
leukocyte emigration: the multistep paradigm. Cell, 76:301–14.
Thomson AW, Nalesnik MA, Rilo HR, et al. 1993. ICAM-1 and E-selectin
expression in lesional biopsies of psoriasis patients responding to
systemic FK 506 therapy. Autoimmunity, 15:215–23.
Todderud G, Nair X, Lee D, et al. 1997. BMS-190394, a selectin inhibitor,
prevents rat cutaneous inflammatory reactions. J Pharmacol Exp Ther,
282:1298–304.
Ulbrich H, Eriksson EE, Lindbom L. 2003. Leukocyte and endothelial
cell adhesion molecules as targets for therapeutic interventions in
inflammatory disease. Trends Pharmacol Sci, 24:640–7.
Varki A. 1994. Selectin ligands. Proc Natl Acad Sci U S A, 91:7390–7.
von Andrian UH, Chambers JD, McEvoy LM, et al. 1991. Two-step model
of leukocyte-endothelial cell interaction in inflammation: distinct roles
for LECAM-1 and the leukocyte beta-2 integrins in vivo. Proc Natl
Acad Sci U S A, 88:7538–42.
von Andrian UH, Mackay CR. 2000. T-cell function and migration. Two
sides of the same coin. N Engl J Med, 343:1020–34.
von Andrian UH, Mempel TR. 2003. Homing and cellular traffic in lymph
nodes. Nat Rev Immunol, 3:867–78.
Weninger W, Ulfman LH, Cheng G, et al. 2000. Specialized contributions
by alpha(1,3)fucosyltransferase-IV and Fuc-TVII during leukocyte
rolling in dermal microvessels. Immunity, 12:665–76.
Yvin JC, Alban S, Franz G. 2002. Anti-inflammatory and healing medicine
based on laminarin sulphate. In PCT Int Appl Patent nr. WO
2002036132 (10.05.2002): France.
Zhao LC, Edgar JB, Dailey MO. 2001. Characterization of the rapid
proteolytic shedding of murine L-selectin. Dev Immunol, 8:267–77.
Zlotnik A, Yoshie O. 2000. Chemokines: a new classification system and
their role in immunity. Immunity, 12:121–7.
Zollner TM, Podda M, Pien C, et al. 2002. Proteasome inhibition reduces
superantigen-mediated T cell activation and the severity of psoriasis
in a SCID-hu model. J Clin Invest, 109:671–9.